The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review
Open accessAbstract
BACKGROUND: The outcomes of patients with surgery- and radiation-refractory meningiomas treated with medical therapies are poorly defined. Published reports are limited by small patient numbers, selection bias, inclusion of mixed histologic grades and stages of illness, and World Health Organization (WHO) criteria changes. This analysis seeks to define outcome benchmarks for future clinical trial design. METHODS: A PubMed literature search was performed for all English language publications on medical therapy for meningioma. Reports were tabulated and analyzed for number of patients, histologic grade, prior therapy, overall survival, progression-free survival (PFS), and radiographic response. RESULTS: Forty-seven publications were identified and divided by histology and prior therapies, including only those that treated patients who were surgery and radiation refractory for further analysis. This included a variety of agents (hydroxyurea, temozolomide, irinotecan, interferon-α, mifepristone, octreotide analogues, megestrol acetate, bevacizumab, imatinib, erlotinib, and gefitinib) from retrospective, pilot, and phase II studies, exploratory arms of other studies, and a single phase III study. The only outcome extractable from all studies was the PFS 6-month rate, and a weighted average was calculated separately for WHO grade I meningioma and combined WHO grade II/III meningioma. For WHO I meningioma, the weighted average PFS-6 was 29% (95% confidence interval [CI]: 20.3%-37.7%). For WHO II/III meningioma, the weighted average PFS-6 was 26% (95% CI: 19.3%-32.7%). CONCLUSIONS: This comprehensive review confirms the poor outcomes of medical therapy for surgery- and radiation-refractory meningioma. We recommend the above PFS-6 benchmarks for future trial design.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wen, P. Y., Macdonald, D. R., Reardon, D. A., Cloughesy, T. F., Sorensen, A. G., Galanis, E., DeGroot, J., Wick, W., Gilbert, M. R., Lassman, A. B., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.3541 · Cited by 3,836
Self-citationResponse criteria for phase II studies of supratentorial malignant glioma.
Macdonald, D. R., Cascino, T. L., Schold, S. C., & Cairncross, J. G. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.7.1277 · Cited by 2,409
Horder, & Harnett, W. L. (1941) · BMJ · doi:10.1136/bmj.1.4186.493 · Cited by 1,314
Travis, W. D., Castile, R., Vawter, G., Shwachman, H., Warwick, W., Burke, B. A., & Skinner, M. (1986) · American Journal of Clinical Pathology · doi:10.1093/ajcp/85.4.419 · Cited by 1,189
Wen, P. Y., Yung, W. K. A., Lamborn, K. R., Dahia, P. L., Wang, Y., Peng, B., Abrey, L. E., Raizer, J., Cloughesy, T. F., Fink, K., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0773 · Cited by 429
Self-citationTreatment of unresectable meningiomas with the antiprogesterone agent mifepristone
Grunberg, S. M., Weiss, M. H., Spitz, I. M., Ahmadi, J., Sadun, A., Russell, C. A., Lucci, L., & Stevenson, L. L. (1991) · Journal of Neurosurgery · doi:10.3171/jns.1991.74.6.0861 · Cited by 379
DEATH DURING THERAPEUTIC STARVATION
Hermann, L. S., & Iversen, M. (1968) · The Lancet · doi:10.1016/s0140-6736(68)92649-4 · Cited by 361
Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma
Kaley, T. J., Wen, P., Schiff, D., Ligon, K., Haidar, S., Karimi, S., Lassman, A. B., Nolan, C. P., DeAngelis, L. M., Gavrilovic, I., et al. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nou148 · Cited by 294
Self-citationBevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series
Lou, E., Sumrall, A. L., Turner, S., Peters, K. B., Desjardins, A., Vredenburgh, J. J., McLendon, R. E., Herndon, J. E., McSherry, F., Norfleet, J., et al. (2012) · Journal of Neuro-Oncology · doi:10.1007/s11060-012-0861-0 · Cited by 196
Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma
Norden, A. D., Raizer, J. J., Abrey, L. E., Lamborn, K. R., Lassman, A. B., Chang, S. M., Yung, W. K. A., Gilbert, M. R., Fine, H. A., Mehta, M., et al. (2010) · Journal of Neuro-Oncology · doi:10.1007/s11060-009-9948-7 · Cited by 196
Self-citationRecurrent meningioma: Salvage therapy with long-acting somatostatin analogue
Chamberlain, M. C., Glantz, M. J., & Fadul, C. E. (2007) · Neurology · doi:10.1212/01.wnl.0000271382.62776.b7 · Cited by 186
Self-citationTemozolomide for treatment-resistant recurrent meningioma
Chamberlain, M. C., Tsao-Wei, D. D., & Groshen, S. (2004) · Neurology · doi:10.1212/01.wnl.0000118300.82017.f4 · Cited by 186
Self-citationGrunberg, S. M., Weiss, M. H., Russell, C. A., Spitz, I. M., Ahmadi, J., Sadun, A., & Sitruk-Ware, R. (2006) · Cancer Investigation · doi:10.1080/07357900601062339 · Cited by 183
Medical therapies for meningiomas
Wen, P. Y., Quant, E., Drappatz, J., Beroukhim, R., & Norden, A. D. (2010) · Journal of Neuro-Oncology · doi:10.1007/s11060-010-0349-8 · Cited by 181
Self-citationMason, W. P., Gentili, F., Macdonald, D. R., Hariharan, S., Cruz, C. R., & Abrey, L. E. (2002) · Journal of Neurosurgery · doi:10.3171/jns.2002.97.2.0341 · Cited by 175
Wen, P. Y., Yung, W. K. A., Lamborn, K. R., Norden, A. D., Cloughesy, T. F., Abrey, L. E., Fine, H. A., Chang, S. M., Robins, H. I., Fink, K., et al. (2009) · Neuro-Oncology · doi:10.1215/15228517-2009-010 · Cited by 162
Self-citationAdjuvant combined modality therapy for malignant meningiomas
Chamberlain, M. C. (1996) · Journal of neurosurgery · doi:10.3171/jns.1996.84.5.0733 · Cited by 127
Self-citationInterferon‐α for recurrent World Health Organization grade 1 intracranial meningiomas
Chamberlain, M. C., & Glantz, M. (2008) · Cancer · doi:10.1002/cncr.23803 · Cited by 116
Self-citationResponse Assessment in Neuro-Oncology
Lee, E. Q., & Wen, P. Y. (2010) · Current Oncology Reports · doi:10.1007/s11912-010-0143-y · Cited by 112
Self-citationSalvage chemotherapy With CPT-11 for recurrent meningioma
Chamberlain, M. C., Tsao-Wei, D. D., & Groshen, S. G. (2006) · Journal of Neuro-Oncology · doi:10.1007/s11060-005-9093-x · Cited by 109
Self-citationHydroxyurea Chemotherapy for Unresectable or Residual Meningioma
Newton, H. B., Slivka, M. A., & Stevens, C. (2000) · Journal of Neuro-Oncology · doi:10.1023/a:1026770624783 · Cited by 107
Non-Resectable Slow-Growing Meningiomas Treated by Hydroxyurea
Loven, D., Hardoff, R., Bar‐Sever, Z., Steinmetz, A., Gornish, M., Rappaport, Z. H., Fenig, E., Ram, Z., & Sulkes, A. (2004) · Journal of Neuro-Oncology · doi:10.1023/b:neon.0000021827.85754.8e · Cited by 105
Hydroxyurea for recurrent surgery and radiation refractory high-grade meningioma
Chamberlain, M. C. (2011) · Journal of Neuro-Oncology · doi:10.1007/s11060-011-0741-z · Cited by 96
Self-citationAdvances in meningioma therapy
Norden, A. D., Drappatz, J., & Wen, P. Y. (2009) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-009-0034-5 · Cited by 95
Self-citationPhase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma
Reardon, D. A., Norden, A. D., Desjardins, A., Vredenburgh, J. J., Herndon, J. E., Sykes, A. D., Sampson, J. H., Gururangan, S., Peters, K. B., McLendon, R. E., et al. (2011) · Journal of Neuro-Oncology · doi:10.1007/s11060-011-0687-1 · Cited by 92
Self-citationHydroxyurea for recurrent surgery and radiation refractory meningioma: a retrospective case series
Chamberlain, M. C., & Johnston, S. K. (2011) · Journal of Neuro-Oncology · doi:10.1007/s11060-011-0541-5 · Cited by 75
Self-citationRaizer, J. J., Abrey, L. E., Lassman, A. B., Chang, S., Lamborn, K. R., Kuhn, J. G., Yung, W. K. A., Gilbert, M. R., Aldape, K., Wen, P. Y., et al. (2009) · Neuro-Oncology · doi:10.1093/neuonc/nop017 · Cited by 56
Self-citation
Cited by
EANO guidelines for the diagnosis and treatment of meningiomas
Goldbrunner, R., Minniti, G., Preusser, M., Jenkinson, M. D., Sallabanda, K., Houdart, E., von Deimling, A., Stavrinou, P., Lefranc, F., Lund-Johansen, M., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30321-7 · Cited by 854
EANO guideline on the diagnosis and management of meningiomas
Goldbrunner, R., Stavrinou, P., Jenkinson, M. D., Sahm, F., Mawrin, C., Weber, D. C., Preusser, M., Minniti, G., Lund-Johansen, M., Lefranc, F., et al. (2021) · Neuro-Oncology · doi:10.1093/neuonc/noab150 · Cited by 742
Self-citationResponse Assessment in Neuro-Oncology Clinical Trials
Wen, P. Y., Chang, S. M., Van den Bent, M. J., Vogelbaum, M. A., Macdonald, D. R., & Lee, E. Q. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.72.7511 · Cited by 435
Self-citationOncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma
Abedalthagafi, M., Bi, W. L., Aizer, A. A., Merrill, P. H., Brewster, R., Agarwalla, P. K., Listewnik, M. L., Dias-Santagata, D., Thorner, A. R., Van Hummelen, P., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/nov316 · Cited by 293
Self-citation
Metadata
- Authors
- Kaley, T., Barani, I., Chamberlain, M., McDermott, M., Panageas, K., Raizer, J., Rogers, L., Schiff, D., Vogelbaum, M., Weber, D., & Wen, P.
- Venue
- Neuro-Oncology
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-02-04
- Volume
- 16
- Issue
- 6
- Pages
- 829-840
- ISSN
- 1522-8517 (ISSN-L)
- 1523-5866
- OpenAlex
- W1988927456
- Cited by
- 270
- References
- 27
- FWCI
- 13.26
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.